Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Labels

March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
rareconnect.org TMAU

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :
https://forms.gle/vem2TjepKobYZPBu8

current participants : 113 (update 18dec20)

Monday, February 15, 2021

Messina lab has TMAU - brain chemistry theory (paper)

Messina genetics lab new TMAU paper on TMAU affecting brain chemistry.

Seem to be a theory whereby TMA might affect the brain negatively (physiology, not psychologically).
This is a new theory it seems, put forward by only this lab currently. 

Messina genetics lab in Italy has a long interest in TMAU, and seems to do TMAU research.
It's the Italian lab mentioned in the previous post.

The full paper is here : link to paper
Gut-Brain Axis Cross-Talk and Limbic Disorders as Biological Basis of Secondary TMAU
by Luigi Donato, Simona Alibrandi, Concetta Scimone, Andrea Castagnetti, Giacomo Rao, Antonina Sidoti and Rosalia D’Angelo

Some quotes :

Background: Trimethylaminuria (TMAU) is a rare metabolic syndrome characterized by the accumulation and the excretion of trimethylamine (TMA), a volatile diet compound produced by gut microbiota. Gut microbiota alterations are mainly involved in the secondary TMAU, whose patients show also different psychiatric conditions. We hypothesized that the biological activity of several molecules acting as intermediate in TMA metabolic reaction might be at the basis of TMAU psychiatric comorbidities. Methods: To corroborate this hypothesis, we performed the analysis of microbiota of both psychiatric suffering secondary TMAU patients and TMAU “mentally ill” controls, comparing the alteration of metabolites produced by their gut bacteria possibly involved in neurotransmission and, in the same time, belonging to biochemical pathways leading to TMA accumulation. Results: Microbiota analyses showed that Clostridiaceae, Lachnospiraceae and Coriobacteriaceae alterations represented the bacterial families with highest variations. This results in an excessive release of serotonin and an hyperactivation of the vagus nerve that might determine the widest spectrum of psychiatric disorders shown by affected patients. These metabolites, as short chain fatty acids, lactate and neurotransmitter precursors, are also related to TMA accumulation. Conclusions: Knowledge of microbiota-gut-brain axis may become a potential new strategy for improving metabolic diseases and to treat linked psychiatric disorders.


Conclusion

The relationship between gut microbiota and psychiatric disturbs is one of the most challenging topics involving researchers. The vagal nerve is the anatomical structure which permits the communication between the central nervous system (CNS) and enteric nervous system (ENS). Vagal afferent neurons express receptors for gut microbiota metabolites, such as serotonin, that can modulate nutrient metabolism. Furthermore, SCFAs, catecholamines, acetylcholine, the intermediates of mixed acid fermentation and TMAO are able to regulate metabolism through a microbiota-gut-liver axis. However, very little is known about the direct connection between metabolic diseases and mental disorders, involving common pathway in which the considered metabolites play an orchestral role. In our retrospective comparison, we laid the bases for further investigation about biochemical and biological link between secondary trimethylaminuria and psychiatric behaviors. We suppose that the mental disturbs affecting TMAU patients are probably not only related to social consequence of their metabolic disease but also to a physiopathological effect determined by TMA accumulation. The knowledge of this aspects might allow us to personally modulate each gut microbiota. Thus, the related microbiota-gut-brain axis may become a potential new strategy for improving prognosis of metabolic diseases and treat linked psychiatric disorders.
  

get New Posts by EMAIL : Enter your email address :


A EURORDIS and NORD Member Organization

1 comments:

Anonymous said...

interesting
https://onlinelibrary.wiley.com/doi/full/10.1002/advs.201903697

Feb 28, 2021, 2:28:00 AM
Post a Comment